Trial Profile
A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Activated T cells (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors Xcyte Therapies
- 31 Jan 2017 New trial record